Rapid Micro Biosystems, Inc.
RPID Nasdaq· Laboratory Analytical Instruments
Last close · Oct 23, 2026
$0.78
KIRA · Stoqly’s AI analyst, in plain words
- Rapid Micro Biosystems, Inc. had $33.6M of revenue in fiscal 2025, up 19.7% on the year before. Over five years, revenue changed +15.9% a year on average.
- Its operating margin was −141.1%, up 36.9 pts: of every 100 in sales, about −141 is left after running the business.
- Rapid Micro Biosystems, Inc. lost $47.1M in fiscal 2025.
- Free cash flow was −$31.9M in fiscal 2025, −95.0% of revenue.
- Rapid Micro Biosystems, Inc. has $19.2M more cash than debt.
Market cap
$37.7M
P/E
—
Revenue
$33.6M
Net income
−$47.1M
Free cash flow
−$31.9M
Operating margin
−141.1%
Rapid Micro Biosystems, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+19.7%
Yes. Sales grew 19.7% last year.
Does it make a profit?
−140.3%
No. It lost money last year.
Does profit turn into cash?
−95.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Rapid Micro Biosystems, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- RAPID MICRO BIOSYSTEMS, INC.
- CIK
- 0001380106
Rapid Micro Biosystems, Inc. · RPID
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $23.2M | $17.1M | $22.5M | $28.1M | $33.6M |
| Revenue growth | 44.5% | −26.3% | 31.4% | 24.6% | 19.7% |
| Net interest income | −$2.6M | $1.8M | $4.2M | — | — |
| Operating margin | −203.3% | −369.0% | −251.2% | −178.0% | −141.1% |
| Net income | −$73.5M | −$60.8M | −$52.5M | −$46.9M | −$47.1M |
| Net margin | −316.5% | −354.9% | −233.0% | −167.2% | −140.3% |
| Diluted EPS | −$3.94 | −$1.43 | −$1.22 | −$1.08 | −$1.05 |
| Cash | |||||
| Cash from operations | −$55.0M | −$58.5M | −$45.1M | −$44.2M | −$31.1M |
| Capital expenditure | $3.2M | $6.7M | $1.8M | $1.4M | $0.9M |
| Free cash flow | −$58.2M | −$65.3M | −$46.9M | −$45.5M | −$31.9M |
| FCF margin | −250.4% | −381.1% | −208.4% | −162.3% | −95.0% |
| Share count change | 5,416.9% | 114.6% | 1.3% | 1.3% | 2.5% |
| Debt and strength | |||||
| Cash and short-term investments | $193M | $109M | $92.1M | $50.7M | $38.3M |
| Debt incl. finance leases | $0.0M | $0.3M | — | $0.2M | $19.1M |
| Shareholders' equity | $221M | $164M | $118M | $75.4M | $33.2M |
| Current ratio | 12.0x | 7.3x | 6.3x | 4.6x | 3.3x |
| Interest coverage | −17.8x | — | — | −1,248.0x | −43.5x |
| Returns and quality | |||||
| Return on capital | −135.8% | −90.0% | — | −160.2% | −271.1% |
| Return on equity | −156.5% | −31.6% | −37.2% | −48.5% | −86.8% |
| Return on tangible equity | −35.3% | −37.0% | −44.5% | −62.2% | −141.9% |
| Piotroski F-score | 4 | 1 | 2 | 2 | 2 |
| Altman Z'' | 11.4 | 2.0 | −2.9 | −11.5 | −22.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$1.1M
5 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Rapid Micro Biosystems, Inc. · RPID
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.78 a share, the company is worth $37.7M.
Source: SEC EDGAR XBRL filings (CIK 0001380106). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.